Roche’s Genentech has completed the structural framework of its new $2-billion biomanufacturing facility in Holly Springs, North Carolina. Additionally, the company has announced plans to invest approximately $750 million in a new device fill–finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon. The investment will bring new end-to-end device filling capabilities to the site and more than double the size of the existing facility. 

Once operational, the biomanufacturing facility in North Carolina will produce treatments for metabolic conditions, such as obesity. It will incorporate biomanufacturing, automation, robotics, and digital manufacturing technologies. The facility is part of Roche’s and Genentech’s broader $50-billion commitment to research and development (R&D) and manufacturing infrastructure in the US. Roche’s and Genentech’s current US footprint includes 13 manufacturing sites, 15 R&D sites, and approximately 25,000 employees across 24 locations in eight states. 

The new fill–finish facility will support the manufacturing of advanced drug-delivery devices, such as pre-filled syringes and autoinjectors. Designed for flexibility, the facility will be capable of both high- and low-volume device filling across a broad range of Genentech’s portfolio, enabling the site to respond to changing manufacturing needs as the company’s portfolio evolves. Commercial operations are expected to begin in 2031. 

Source: Genentech (device fill-finish facility) and Genentech (biomanufacturing facility)